Search

See Pharmaceutical Reviews Update – Issue 19 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include:

• New guidance for providing patient input
• New webpage for provisional funding algorithms

See Pharmaceutical Reviews Update – Issue 18 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include:

• updates on communications and web pages for CADTH drug reimbursement reviews
• updates on clinician group input.

See Pharmaceutical Reviews Update – Issue 17 for important news and information related to CADTH’s drug review programs. Highlights from this issue include:

• new procedures for CADTH drug reimbursement reviews
• a revised provisional algorithm process
• a revised CADTH fee schedu...

See Pharmaceutical Reviews Update – Issue 16 for important news and information related to CADTH’s drug review programs. Highlights from this issue include:

• a consultation on CADTH’s drug reimbursement review procedures
• a consultation on the Health Canada, CADTH, and INESSS aligned review ...

Highlights from this issue include:

• Questions and answers regarding CADTH’s pharmaceutical review programs and COVID-19
• Postponement of consultations on CADTH’s aligned drug review processes
• New Canadian Plasma Protein Product Expert Committee
• Revised pr...

See Pharmaceutical Reviews Update – Issue 14 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include:

• A minor revision to the procedure for the sponsor’s review of initial CADTH pCODR Clinical and Economic Reports
• Pending consultation o...

Highlights from this issue include:

• New consolidated document for pCODR procedures and guidelines
• Clarifications regarding economic submission requirements
• Update for patients and communities

Highlights from this issue include:

• A new process for the submission and review of cell and gene therapies
• Updated guidelines on fees for CADTH pharmaceutical reviews
• Pending updates to the category 1 requirements
• Pending changes to CADTH conflict of interest policies
• A reminder...

Highlights from this issue include:

• Information on the CADTH Drug Portfolio Information Session
• A new interim plasma protein product review process
• Details on the expansion of CADTH’s tailored review and therapeutic review processes
• Revised processes for checkpoint meetings
• Pend...

Highlights from this issue include:

• an extension of the feedback period on the ongoing consultations
• an updated procedure for implementation-phase clinical panels
• the upcoming announcement of a pilot process for plasma-related drugs.